APA

Walton M. I., Eve P. D., Hayes A., Valenti M., De Haven Brandon A., Box G., Boxall K. J., Aherne G. W., Eccles S. A., Raynaud F. I., Williams D. H., Reader J. C., Collins I. & Garrett M. D. (20100322). The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. : Molecular cancer therapeutics.

Chicago

Walton Michael I, Eve Paul D, Hayes Angela, Valenti Melanie, De Haven Brandon Alexis, Box Gary, Boxall Kathy J, Aherne G Wynne, Eccles Suzanne A, Raynaud Florence I, Williams David H, Reader John C, Collins Ian and Garrett Michelle D. 20100322. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. : Molecular cancer therapeutics.

Harvard

Walton M. I., Eve P. D., Hayes A., Valenti M., De Haven Brandon A., Box G., Boxall K. J., Aherne G. W., Eccles S. A., Raynaud F. I., Williams D. H., Reader J. C., Collins I. and Garrett M. D. (20100322). The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. : Molecular cancer therapeutics.

MLA

Walton Michael I, Eve Paul D, Hayes Angela, Valenti Melanie, De Haven Brandon Alexis, Box Gary, Boxall Kathy J, Aherne G Wynne, Eccles Suzanne A, Raynaud Florence I, Williams David H, Reader John C, Collins Ian and Garrett Michelle D. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. : Molecular cancer therapeutics. 20100322.